Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Overland Park, Kansas Clinical Trials

A listing of Overland Park, Kansas clinical trials actively recruiting patient volunteers.

RESULTS

Found (220) clinical trials

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Prior to starting treatment individuals being considered for this study will be evaluated to determine if they are eligible to participate in the study. There are certain prestudy test that are required: physical exam, blood tests, ECG, chest x-ray, bone marrow aspirate and biopsy to confirm the diagnosis of AML. ...

Phase

8.47 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks in male and female subjects 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 subjects ...

Phase

8.96 miles

Learn More »

Study of the Efficacy and Safety of DigiFab in Antepartum Subjects With Severe Preeclampsia

This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.

Phase

8.96 miles

Learn More »

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.

Phase

8.96 miles

Learn More »

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Although there are several studies supporting the efficacy of tocilizumab (TCZ) in Rheumatoid Arthritis (RA) and systemic onset juvenile idiopathic arthritis, it's use in other autoimmune disorders has also been propose. A consensus statement on blocking the effects of IL-6 in RA and other autoimmune conditions has been recently published. ...

Phase

8.96 miles

Learn More »

Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)

Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for researchers, clinicians, patients, and health care underwriters such as Medicare, is the role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment ...

Phase

8.96 miles

Learn More »

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

PRIMARY OBJECTIVES: I. To study the use of ibrutinib starting between day 60 and day 90 after allogeneic hematopoietic cell transplant (HCT) until 12 months post hematopoietic cell transplant to improve the progression-free survival (PFS) at 12 months post hematopoietic cell transplant by 25% compared to historical controls. SECONDARY OBJECTIVES: ...

Phase

8.96 miles

Learn More »

Evaluating the Safety Pharmacokinetics and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.

Phase

8.96 miles

Learn More »

A Study to Assess the Efficacy and Safety of H.P. Acthar Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

This is a multicenter, multiple dose study to examine the effect of Acthar on functional decline in adult subjects with amyotrophic lateral sclerosis (ALS). Approximately 213 subjects will be enrolled. Following a screening period of up to 28 days, subjects with ALS and symptom onset (defined as first muscle weakness ...

Phase

8.96 miles

Learn More »

A Phase 2 RCT Study of CX-8998 for Essential Tremor

This is a multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on primidone at baseline who will be allowed 6 weeks of screening to allow for safe discontinuation). Screening results from all patients meeting the eligibility requirements will ...

Phase

8.96 miles

Learn More »